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Polysaccharide Peptide: A promising Anti 
Inflammation and Anti Oxidant in Atherosclerosis
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Background : Heart disease is the leading cause of death for both men 
and women, but heart disease is preventable and controllable. Ganoderma 
lucidum is widely used as traditional medicine for centuries particularly in 
China, Japan, and Korea. Previous study showed antioxidative activity of 
polysaccharide peptide (PsP) from Genoderma lucidum.
Objective : This study was aimed to evaluate anti-inflammatory and anti-
oxidant effect of polysaccharide peptide (PsP) from Ganoderma lucidum 
in atherosclerotic rats.
Methods : The atherosclerotic rats were randomly divided into four groups 
(5 rats each group) : atherosclerotic model with high-fat diet, low dose PsP 
treated group (50 mg/kgBW), medium dose PsP treated group (150 mg/
kgBW), high dose PsP treated group (300 mg/kgBW), with normal mice 
used as a control group. Parameters measured were the level of MDA, 
SOD, IL - 6 , IL - 10, hsCRP, TNF - α, lipid profile and foam cell. 
Results : After PsP therapy for 5 weeks, the levels of MDA (p=0.01), hsCRP 
(p=0.018) in rats model of atherosclerosis decrease significantly. PsSP can 
reduce levels of IL - 6 (p=0.933) and increase levels of SOD (p=0.28) de-
scriptively at PsP doses 150 mg/kgBW. While the levels of TNF-α (p=0.894) 
and IL-10 (p=0.98) was not affected by administration of PsP. PsP improve 
the lipid profile by increasing HDL (p=0.002) and lowering total cholesterol 
(p=0.04). The formation of foam cells (p=0.024) as a marker of athero-
genesis significantly decreased by administration of PsP . 
Conclusion : PSP can be useful to reduce inflammatory processes and 
oxidative stress to prevent the process of atherogenesis .
(J Kardiol Indones. 2015;36:22-7)
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Penelitian Klinis
Latar belakang: Penyakit jantung adalah merupakan penyebab kematian utama pada pria dan wanita, akan tetapi penyakit 
jantung dapat dicegah dan dikotrol. Ganoderma lucidum telah digunakan selama berabad-abad, khususnya di China, Jepang, 
dan Korea. Pada beberapa penelitian sebelumnya menunjukkan efek antioksidan dari peptida polisakarida yang berasal dari 
Ganoderma lucidum.
Tujuan: Mengevaluasi efek anti-inflamasi serta anti-oksidan dari peptida polisakarida (PsP) ekstrak Ganoderma lucidum pada 
tikus yang diberi paparan diet tinggi lemak. 
Metode: Tikus aterosklerosis dibagi menjadi empat kelompok (5 tikus masing-masing kelompok) : model aterosklerosis dengan 
diet tinggi lemak, diberi terapi PsP dosis rendah (50mg/kgBB), dosis sedang (150mg/kgBB), dan dosis tinggi (300mg/kgBB), 
serta kelompok tikus normal sebagai kontrol negatif. Parameter yang diukur adalah kadar MDA, SOD, IL-6, IL-10, hsCRP, 
TNF-α, profil lipid dan juga foam cell. 
Hasil: Setelah pemberian terapi PsP selama 5 minggu, kadar MDA (p=0.01), hsCRP (p=0.018) pada tikus model atherosklerosis 
dapat turun secara signifikan. Pemberian PsP dapat menurunkan kadar IL-6 (p=0.933) dan meningkatkan kadar SOD (p=0.28) 
secara deskriptif pada dosis PsP 150 mg/kgBB. Sedangkan kadar TNF-α (p=0.894) dan IL-10 (p=0.98) tidak terpengaruh 
dengan pemberian PsP. PsP memperbaiki profil lipid dengan meningkatkan kadar HDL (p=0.002) dan menurunkan Kho-
lesterol total (p=0.04). Pembentukan foam cell (p=0.024) sebagai penanda atherogenesis ternyata menurun secara signifikan 
dengan pemberian PsP. 
Kesimpulan: PsP dapat bermanfaat untuk menurunkan proses inflamasi dan oksidatif stres untuk mencegah proses athero-
genesis.
(J Kardiol Indones. 2015;36:22-7)
Kata kunci: peptida polisakarida (Ganoderma lucidum), anti-inflamasi, anti-oksidan, penyakit kardiovaskuler, atherosklerosis.
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Introduction
Heart disease is one of the leading causes of mortality in 
the world. It is shown that 48 % of deaths in the world 
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related with non-infectious diseases, is cardiovascular 
disease. In 2008, 17.3 million people died from 
cardiovascular disease, heart attack 7.3 million and 
6.2 million due to stroke.1
Atherosclerosis is caused by inflammation or 
chronic inflammation produced by macrophages, 
polymorfonuclear cells, and his cytokines.2
It has recently been developed herbal medicine as 
complementary therapy on CHD patients including 
Ganoderma lucidum. Ganoderma lucidum is a 
favorite ingredient in traditional oriental medicine 
for centuries. Several studies have shown Ganoderma 
Lucidum extract useful on CHD, clinically improving 
clinical complaints, lowering total serum cholesterol, 
improves ECG and blood pressure.v In addition the 
study also showed benefits in Scandinavia, extracts of 
the fungus Saccharomyces cerevisiae wall containing 
β-glucan given to patients undergoing CABG, which 
decreases the inflammatory response and protect the heart 
from reperfusion injury.4 But only limited study focus in 
effect of Ganoderma lucidum in chronic inflammation 
and oxidative stress in atherogenesis.
In this study, the authors aims to prove the effect 
of extracts of Ganoderma lucidum, polysaccharides 
peptide (PsP) that contains bioactive β-D-glucan on 
markers of chronic inflammation and oxidative stress 
in rat given High Fat Diet (HFD).
Methods
This study was designed using the experimental 
method in rats to determine the effect of PsP for the 
treatment of chronic inflammation process. 
This research was conducted at the Central 
Laboratory of Life Sciences Brawijaya (LSIH) 
University of Brawijaya, Malang.
Experimental animals in this study were rats (rattus 
norvegicus) obtained from CV Gamma Scientific 
Biolab, Malang. Inclusion criteria were male rats, 
approximately 3 months of age, weight about 150-
200 grams, healthy condition and no anatomical 
abnormalities. While the exclusion criteria are rats had 
diarrhea during the study period were marked by feces 
is not formed and or lose weight, dead and sick during 
the treatment period, rats throughout the study would 
not eat. Rats drop out if match with exclusion criteria 
and replaced with other rats in accordance with the 
inclusion criteria, in order to get the number of rats 
in accordance with the sample.
PsP made by Sahabat Lingkungan Hidup Surabaya, 
a biopharmaceutical company. PsP extracted from 
mycelia of Ganoderma lucidum. PsP is prepared in dry 
powder form.
A total of 25 rats acclimated with normal food. 
Then the rats were fed with HFD to make a rat model 
of atherosclerosis, whereas rats for the control group 
were given a normal food. After being fed with high fat 
diet for 8 weeks, the rats were divided randomly into 5 
groups: negative control group with normal diet + saline 
solution as a placebo, a positive control group with HFD 
(atherosclerosis)+saline solution as a placebo, then the 
group treated with HFD+saline containing 50, 150, 
300mg/kg PsP for 5 weeks each group consisted of 5 
rats. Diets are made every day given as a daily diet of 
50g/rat/day. Diet gave at the same time during the day 
at 12.00-14.00. A normal feed consisting of chicken 
feed / Pars (with water content, protein, fat, fiber, ash, 
Ca, phosphorus, antibiotic, coccidiostat) 66.6 % and 
33.4% wheat flour.
Measurement of IL-6, IL-10, TNF-α, hsCRP, 
MDA, SOD, lipid profile and foam cells in experimen-
tal animals by taking blood or organs of experimental 
animals. We measured Inflammation marker (IL-6, IL-
10, TNF-α, hsCRP), Oxydative Stress marker (MDA, 
SOD) with ELISA kits and foam cell measurements 
with hematoxylin or HE.
Statistical Analysis
The data were analyzed with the SPSS version 7.0 
software. Descriptive analysis that will be presented 
include the mean value, standard deviation, the lower 
and upper 95% confidence interval, and the minimum 
value of the maximum temptation. Bivariat analysis 
using Oneway Anova was used to identify significant 
difference between at least the two treatment groups in 
all parameters. Post Hoc Test Duncan test will be done if 
one way anova showed significant difference (p < 0.005) 
between at least two treatment groups to identify doses 
of PsP that affects the parameters.
Results
This study was conducted to determine the effect 
of poly- saccharides Peptide (PsP) in inhibiting the 
formation of atherosclerosis in atherosclerosis rats 
induced by HFD. The mechanism of inhibition 
of the formation of atherosclerosis identified by 
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identifying the parameters as follows: MDA, SOD 
(Oxydative Stress marker) IL-6, hsCRP, TNF-α, 
IL-10 (Inflammation Marker), Total Cholesterol, 
Triglycerides, Low Density Lipid (LDL), High Density 
Lipid (HDL) (Lipid Profile), and foam cell.
Oxydative Stress Marker
Lowest MDA levels were observed in the normal 
group. While the highest MDA levels found in 
atherosclerotic group, Descriptively, an increase dose 
of the PSP having an inclination to reduce levels of 
MDA. PsP at dose 300 mgkgBW significantly lowered 
MDA level (p= 0.001) (Figure 1).
PsP showed no correlation with level of SOD 
descriptively and also of bivariate analysis (p = 0.280). 
Lowest SOD observed in the experimental results are 
in atherosclerosis group+PSP 50 mg. While the highest 
levels of SOD found in the atherosclerotic group + 
PSP 150 mg. 
Inflammation Marker
IL-6 level were descriptively reduced with PsP dose 
150 mg/kgBW, the lowest experimental results are in 
atherosclerosis group + PSP 150 mg. Bivariate analysis 
PsP has no correlation with IL-6 level (p=0.933). 
PsP showed significantly reduced of hsCRp 
(p=0,018) in the treatment groups especially in dose 
50 mg/kgBW (Figure 2).
TNF-α and IL-10 levels were not correlated with 
PsP treatment (p=0.894 and p=0.98 respectively). 
Lipid Profile 
PsP treatment decreased cholesterol total level (Figure 
3) and increased HDL level significantly (p=0.04 and 
p=0.002 respectively) at PsP dose 50,150,300 mg/
kgBW, but no correlation with LDL and triglyceride 
level (p=0.129 and p=0.340).
Foam Cell
PsP decreased foam cell count significantly (p=0.024) 
at PsP dose 300 mg/kgBW (Figure 4).
Based on these results there are dose differences to 
get results as expected. To get the reduction in MDA 
levels close to normal until the required dose 300mg/
kgBB. As for getting the lowest levels of hsCRP is 
giving 50mg/kgBB PSP. 
Figure 1. MDA Levels (uM) on HFD Induced Rats.
Figure 2. hsCRP Levels (ng/mL) on HFD Induced Rats.
Figure 3. Total Cholesterol Levels (mg/dl) on HFD Induced 
Rats.
Figure 4. Foam Cell I 10 Fields on HFD Induced Rats.
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In this study also showed that the PSP could 
correct lipid profiles and reduce the levels of foam 
cells. To get the required reduction in total cholesterol 
need PSP 150mg/kgBW or 300mg/kgBW, while to 
be able to increase HDL can use 50mg/kgBW dose, 
150mg/kgBW or 300mg/kgBW. As for lowering the 
number of foam cells to near normal requires a PSP 
with 300mg/kgBB dose.
Discussion
Ganoderma lucidum has been used since hundreds of 
years ago in various countries in the world, but the 
effectiveness and side effects is still in ongoing research. 
Limited study focus in the effect of Ganoderma lucidum 
in atherogenesis especially in chronic inflammation, to 
our knowledge, we conduct the first in this field.
In the study, presented MDA level showed ath-
erosclerotic rats given PSP 300mg/kgBW group was 
significantly different to the normal rats. Interestingly 
in our research PsP can’t increase significantly SOD 
level (p=0.280) although PsP treatment at dose  150mg/
kgBW gave the highest effect in increasing SOD, which 
means higher than normal and atherosclerosis groups. It 
shows that treatment of PsP can be used as anti oxidant 
to reduce oxidative stress, although statistically SOD 
not significantly increased. This result is consistent with 
previous studies. Galor et al, in 2004 in healthy indi-
viduals given showed no significant difference in MDA 
levels between the placebo and treatment groups.5 PSP 
can increase antioxidant defense systems by increasing 
the activity of SOD in the body which are composed 
of antioxidant enzymes that play a role of antioxidant 
nutrients to protect from oxidative stress. In principle 
antioxidant enzymes including SOD, GPX and CAT, 
SOD which catalyzes dysmutase superoxide into oxygen 
and hydrogen peroxidation.6-8
There were conflicting result in our study in 
inflammation marker. Descriptively, giving 150mg 
PSP can reduce levels of IL-6 and lower levels 
of IL-6 than atherosclerosis rats. And there are 
significant differences in the levels of inflammatory 
cytokines hsCRP between the negative control group, 
atherosclerosis, and the treatment group were treated 
with PsP. In the group treated with a dose of 50mg PSP 
turns hsCRP levels of hsCRP levels nearly equivalent 
to the negative control group, whereas if the dose is 
increased to 150mg or 300mg not further lower hsCRP 
levels. But PsP administration seems has no role in 
affecting level of TNF-α and IL-10. Since IL-10 is an 
anti inflammation marker, our study showed reversed 
result, whereas normal rat has higher IL-10 level than 
treatment group.
Previous studies also reveals conflicting result. Galor 
research, at 2004 in healthy individuals no significant 
difference in hsCRP levels between the placebo and 
treatment groups.5 Li’s research in 2007, in a popula-
tion of patients suffering from rheumatoid arthritis 
(RA) with disease-modifying antirheumatic therapy 
drugs (DMARDs) eg hydroxychloroquine, sulfasalazine, 
methotrexate, and leflunomide, also showed no differ-
ence CRP level between placebo groups were given ad-
ditional therapy extract ganoderma 4 g in combination 
with other herbs for the treatment of 24 weeks.9 Several 
studies also show different result in different design. 
Ganoderma lucidum increases IL-10 level 10-12 increases 
TNF-α13 and no correlation with IL-6 level in cancer 
patients.14 But none of the previous studies focus on 
inflammatory aspect of atherosclerosis.
In this study, administration of PsP in rats by 
exposure to high fat diet, the fix the lipid profile. 
Blood cholesterol and HDL levels found statistically 
significant differences (p=0.04 and p=0.02 respectively) 
between treatment groups by administering doses of 
PSP 50, 150 and 300 mg/kgBW. Li, 2011 on research 
on rats model of streptozotocin-induced diabetes 
mellitus also shows the effect antihiperglikemia and 
anticholesterol-emia.9 These results are in contrast to 
studies of Seto, et al 2009 in obese diabetic rats models 
+ db / + db Ganoderma lucidum treated for 4 weeks, 
did not give the effect of anti- dyslipidemia, lipid 
profile picture does not improve after administration 
of Ganoderma lucidum.15
Atherogenesis is clearly inhibited with PsP 
treatment. Foam cell, results of chronic inflammation 
and oxidative stress decreased significantly (p=0.000). 
Giving PSP with increasing doses with optimum dose 
300 mg/kgBB tend to be followed by a decline seen the 
average number of Foam Cell. This result sthrengtens 
study by You and Lin in 2002, showed that Ganoderma 
lucidum polysaccharides peptide can inhibit foam cell 
formation and necrosis of macrophages.16
Limitation of this study is conflicting results 
especially in marker of inflammation probably due 
to short duration (5 weeks) of treatment of PsP, 
whereas other studies usually used at least 8 weeks 
of treatment.17 Also, PsP administration given at 9th 
week, after 8 weeks rats fed with HFD, means chronic 
inflammation and oxidative stress is longer than 
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treatment given. Probably that PsP is more useful as 
prevention than treatment. 
Conclusions
PsP administration at dose 50,150,300 mg/kgBW 
is a promising prevention or treatment as anti 
inflammation and anti oxidant thus inhibiting 
atherogenesis in CHD.
Further research is needed to evaluate safety and 
efficacy of PsP in human by conducting toxicity and 
cohort study. 
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